Svelte Medical Systems has commenced First Assessment of the Acrobat Stenting Technique European Post-Market Registry (FAASTER) study.
The multi-center registry study, which will enroll up to 1,500 patients, is designed to evaluate the procedural success and resource utilization associated with the Svelte coronary stent mounted on an integrated delivery system (IDS) in relation to target lesion and vessel complexity and selected catheter approach.
Data presented at Euro PCR meeting in Paris, France in May 2102 suggest that the Svelte IDS reduces radiation exposure, contrast use, adjunctive interventional product use and overall procedure time when compared with conventional stent systems.
Svelte Medical Systems president and CEO Mark Pomeranz said the FAASTER registry is part of the company's ongoing efforts to collect valuable customer feedback and assess the clinical utility of Svelte IDS.
"We hope to more broadly demonstrate the clinical and economic benefits associated with the use of our 'All-In-One' integrated delivery system," Pomeranz added.